Publisher Correction: GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice

AI Insight

This article is a Publisher Correction notice from Nature for a study investigating a novel therapeutic approach combining quintuple agonism targeting GLP-1R, GIPR, and PPARα/γ/δ receptors simultaneously in mouse models of obesity and diabetes. The original research reportedly demonstrated that this multi-receptor agonist compound was capable of correcting both obesity and type 2 diabetes phenotypes in mice. However, as this document is solely a correction notice, the specific nature of the erratum, the corrected data, and the full experimental details of the original study are not available for independent assessment here.

Why it matters

Multi-target receptor agonism combining incretin receptors (GLP-1R, GIPR) with PPAR nuclear receptors represents a potentially more comprehensive pharmacological strategy for metabolic disease than current single or dual agonists such as semaglutide or tirzepatide, which could have significant implications for future obesity and diabetes treatment development.